Skip to main content

Allan Douglas Kirk, MD, PhD

David C. Sabiston, Jr. Distinguished Professor of Surgery
Chair, Department of Surgery
Professor of Surgery
Professor in Pediatrics
Professor in the Department of Immunology
Campus Mail: DUMC 3704, Durham, NC 27710

I am a surgeon with interest in immune management of transplant recipients. I am particularly interested in therapies that influence T cell costimulation pathways and adjuvant therapies that facilitate costimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. I am also interested in understanding how injury, such as that occurring during trauma or in elective surgery, influences immune responses and subsequent healing following injury.

Costimulation Blockade in Organ Transplantion

Allan D. Kirk, MD, PhD, Department of Surgery Chairman
David C. Sabiston, Jr. Professor of Surgery

Education and Training

  • Fellow, Multi Organ Transplantation, University of Wisconsin at Madison, 1995 - 1997
  • Chief Resident, Surgery, Duke University, 1994 - 1995
  • Senior Resident, Surgery, Duke University, 1992 - 1994
  • Research Fellow, Surgery, Duke University, 1989 - 1992
  • Intern & Junior Resident, Surgery, Duke University, 1987 - 1989
  • Ph.D., Duke University, 1992
  • M.D., Duke University School of Medicine, 1987
  • B.S., Old Dominion University, 1983

Selected Grants

Publications

Baumgartner, Roxanne E., Noelle B. Patterson, Justin Berning, Linda Burkly, Rhonda Germond, David M. Harlan, Robert Kampen, Douglas K. Tadaki, Sharda G. Sabnis, and Allan D. Kirk. “RHESUS RENAL ALLOGRAFTS CONTAIN NON-DESTRUCTIVE ACTIVATED LYMPHOCYTIC INFILTRATES FOLLOWING ANTI-CD154 THERAPY.” In Transplantation, 67:S63–S63. Ovid Technologies (Wolters Kluwer Health), 1999. https://doi.org/10.1097/00007890-199904150-00254.

Full Text

Burlingham, W. J., P. J. O’Connell, J. D. Pirsch, B. N. Becker, A. D. Kirk, L. M. Jacobson, L. T. Chin, et al. “STABILITY OF THE TOLERANCE PHENOTYPE AFTER WITHDRAWAL OF IMMUNOSUPPRESSIVE DRUG THERAPY: INFLUENCE OF LOCAL AND GENETIC FACTORS INFLUENCING TNFα AND TGFβ EXPRESSION.” In Transplantation, 67:S69–S69. Ovid Technologies (Wolters Kluwer Health), 1999. https://doi.org/10.1097/00007890-199904150-00278.

Full Text

Elster, E. A., R. L. Kampen, K. A. Robson, D. K. Tadaki, P. Perdue, R. M. McCarron, and A. D. Kirk. “Apoptosis regulatory genes BCL-2 and BAX are induced immediately following ischemic/reperfusion injury.” Surgical Forum 50 (1999): 383–84.

Scholars@Duke

Kenyon, N. S., M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi. “Engraftment and long-term survival of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154 (hu5c8).” In Diabetes, 48:A59–A59. AMER DIABETES ASSOC, 1999.

Scholars@Duke

Burlingham, W., S. Kusaka, L. Chin, D. Hullett, S. Knechtle, H. Sollinger, T. Oberley, J. Pirsch, A. D. Kirk, and B. N. Becker. “Focal infiltrates in kidney allografts: developing a model for clinical transplant peripheral tolerance.” Graft 2 (1999): 253–60.

Scholars@Duke

Kirk, A. D. “Let’s blame the little guys: platelets as an instigator of allograft rejection.” Graft, 1999.

Scholars@Duke

Kirk, A. D. “Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories.” Crit Rev Immunol 19, no. 5–6 (1999): 349–88.

Scholars@Duke

Armstrong, N., P. Buckley, T. Oberley, J. Fechner, Y. Dong, X. Hong, A. Kirk, D. Neville, and S. Knechtle. “Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9.” Transplantation 66, no. 1 (July 15, 1998): 5–13. https://doi.org/10.1097/00007890-199807150-00002.

Full Text

Harlan, D. M., and A. D. Kirk. “Anti-CD154 therapy to prevent graft rejection.” Graft 1 (1998): 63–63.

Scholars@Duke

Pages